Pertuzumab (brand name Perjeta), a recombinant humanized monoclonal antibody developed by Roche/Genentech, targets HER2s extracellular dimerization domain. It is indicated for HER2positive breast cancer (early neoadjuvant/adjuvant, metastatic) in combination with trastuzumab and chemotherapy. Its mechanism blocks HER2 heterodimerization, inhibiting downstream signaling and inducing apoptosis. - Antikörper
Tag:
Mouse IgG1 | Mouse Kappa
Buffer:
PBS, pH7.4
Purity:
0.95
Form:
Liquid
Target:
Human Pertuzumab
* VAT and and shipping costs not included. Errors and price changes excepted
